根据珠子的大小评估药物洗脱珠子经动脉化疗栓塞术 (DEB-TACE) 治疗小肝细胞癌 (HCC) 的效果。 这项回顾性研究包括 212 名来自 5 个三级肿瘤的单发 HCC ≤ 5 cm 的患者。机构。 109 名患者接受 70-150 µm 多柔比星 DEB 治疗（A 组），103 名患者接受 100-300 µm 多柔比星 DEB（B 组）。初始肿瘤缓解（DEB-TACE 后 3 周至 2 个月评估）、局部肿瘤进展时间 (TTLTP)、受限平均完全缓解持续时间 (RMDCR)、并发症发生率、栓塞后综合征发生率和持续时间比较两组患者的住院时间。采用Logistic回归分析初始肿瘤缓解的预后因素。A组和B组的初始客观缓解率分别为91.7%（100/109）和84.5%（87/103）（P = 0.101）。在肿瘤≤3 cm的亚组分析中，A组和B组的初始客观缓解率分别为94.6%（53/56）和78.0%（39/50）（P = 0.012）。 24 个月时的 TTLTP（中位值，A 组为 23.7 个月，B 组为 19.0 个月；P = 0.278 [对数秩]，0.190 [多变量 Cox 回归]）或 RMDCR（11.4 个月与 B 组）没有显着差异。分别为 8.5 个月；P = 0.088）。在肿瘤>3cm的亚组分析中，A组24个月时的RMDCR显着长于B组（11.8个月vs.5.7个月，P = 0.024）。 B 组 DEB-TACE 后轻度胆管扩张的发生率显着高于 A 组（5.5% [6/109] vs. 18.4% [19/103]，P = 0.003）。DEB-TACE 采用 70-与较大的 DEB (100-300-μm) 相比，150-μm 微球在 ≤3-cm HCC 中表现出更高的初始客观缓解率，在 3.1-5-cm HCC 中表现出更长的 24 个月 RMDCR。版权所有 © 2024放射学。

To evaluate the outcomes of drug-eluting bead transarterial chemoembolization (DEB-TACE) according to the size of the beads for the treatment of small hepatocellular carcinoma (HCC).This retrospective study included 212 patients with a single HCC ≤5 cm from five tertiary institutions. One hundred and nine patients were treated with 70-150-µm doxorubicin DEBs (group A), and 103 patients received 100-300-µm doxorubicin DEBs (group B). The initial tumor response (assessed between 3 weeks and 2 months after DEB-TACE), time to local tumor progression (TTLTP), restricted mean duration of complete response (RMDCR), rate of complications, incidence of post-embolization syndrome, and length of hospital stay were compared between the two groups. Logistic regression was used to analyze prognostic factors for initial tumor response.The initial objective response rates were 91.7% (100/109) and 84.5% (87/103) for groups A and B, respectively (P = 0.101). In the subgroup analysis of tumors ≤3 cm, the initial objective response rates were 94.6% (53/56) and 78.0% (39/50) for groups A and B, respectively (P = 0.012). There was no significant difference in the TTLTP (median, 23.7 months for group A vs. 19.0 months for group B; P = 0.278 [log-rank], 0.190 [multivariable Cox regression]) or RMDCR at 24 months (11.4 months vs. 8.5 months, respectively; P = 0.088). In the subgroup analysis of tumors >3-cm, the RMDCR at 24 months was significantly longer in group A than in group B (11.8 months vs. 5.7 months, P = 0.024). The incidence of mild bile duct dilatation after DEB-TACE was significantly higher in group B than in group A (5.5% [6/109] vs. 18.4% [19/103], P = 0.003).DEB-TACE using 70-150-µm microspheres demonstrated a higher initial objective response rate in ≤3-cm HCCs and a longer RMDCR at 24 months in 3.1-5-cm HCCs compared to larger DEBs (100-300-µm).Copyright © 2024 The Korean Society of Radiology.